Taysha Gene Therapies holder plans 200,000-share sale

Taysha Gene Therapies, Inc. shareholder Sukumar Nagendran filed to sell up to 200,000 shares of common stock through Jefferies LLC on or after 07/10/2026 on Nasdaq.

Rhea-AI Filing Summary

Taysha Gene Therapies, Inc. shareholder Sukumar Nagendran filed to sell up to 200,000 shares of common stock through Jefferies LLC on or after 07/10/2026 on Nasdaq. The proposed sale has an aggregate market value of $1,298,000. The filer reports prior sales of 200,000 shares during the past three months for $831,300, and discloses stock option grants of 132,063 shares on 01/02/2024 and 67,937 shares on 01/02/2025.

Key Figures

Planned shares to be sold: 200,000 shares Aggregate market value of planned sale: $1,298,000 Shares sold in past three months: 200,000 shares +4 more

7 metrics

Planned shares to be sold 200,000 shares Common stock to be sold through Jefferies LLC on or after 07/10/2026 on Nasdaq

Aggregate market value of planned sale $1,298,000 Value of 200,000 common shares proposed for sale

Shares sold in past three months 200,000 shares Common stock sold on 04/10/2026

Proceeds from past three-month sale $831,300.00 Total proceeds from 200,000 shares sold on 04/10/2026

Stock option grant 2024 132,063 shares Stock Option Grant dated 01/02/2024 from Taysha Gene Therapies, Inc.

Stock option grant 2025 67,937 shares Stock Option Grant dated 01/02/2025 from Taysha Gene Therapies, Inc.

Planned sale date 07/10/2026 Approximate date of sale for 200,000 shares on Nasdaq

Key Terms

Stock Option Grant, Securities To Be Sold, Securities Sold During The Past 3 Months, aggregate market value

4 terms

Stock Option Grant financial

"Common | 01/02/2024 | Stock Option Grant | Taysha Gene Therapies, Inc."

Securities To Be Sold regulatory

"144: Securities To Be Sold Common | 01/02/2024 | Stock Option Grant"

Securities Sold During The Past 3 Months regulatory

"144: Securities Sold During The Past 3 Months Sukumar Nagendran"

aggregate market value financial

"Common | Jefferies LLC ... | 200000 | 1298000.00 |"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What share sale is disclosed for Taysha Gene Therapies (TSHA) in this Form 144?

The filing discloses a proposed sale of 200,000 shares of Taysha Gene Therapies common stock. The shares are to be sold through Jefferies LLC on Nasdaq on or after 07/10/2026, with an aggregate market value of $1,298,000.

Who is the selling security holder in the TSHA Form 144 notice?

The selling security holder is Sukumar Nagendran, listed with an address at 3000 Pegasus Park Drive, Suite 1430, Dallas, TX 75247. The notice covers a planned sale of 200,000 shares of Taysha Gene Therapies common stock through Jefferies LLC.

What is the aggregate market value of TSHA shares proposed to be sold?

The aggregate market value of the proposed sale is $1,298,000. This value corresponds to the planned sale of 200,000 shares of Taysha Gene Therapies common stock to be executed on or after 07/10/2026 on Nasdaq.

What TSHA stock sales occurred during the past three months under this Form 144?

The filing reports that 200,000 shares of Taysha Gene Therapies common stock were sold on 04/10/2026 for total proceeds of $831,300. This disclosure appears in the Securities Sold During The Past 3 Months section.

What stock option grants related to TSHA are referenced in the Form 144?

The notice references two stock option grants from Taysha Gene Therapies, Inc.: one for 132,063 shares dated 01/02/2024 and another for 67,937 shares dated 01/02/2025. These grants are listed in the Securities To Be Sold section as background.

Through which broker and market will the TSHA shares be sold?

The proposed sale will be executed through Jefferies LLC, located at 520 Madison Avenue, 4th Floor, New York, NY 10022. The 200,000 Taysha Gene Therapies common shares are indicated to be sold on the Nasdaq market on or after 07/10/2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/10/2026 - 04:21 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001665124
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Taysha Gene Therapies, Inc.
SEC File Number	001-39536
Address of Issuer	3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TEXAS 75247
Phone	(214) 612-0000
Name of Person for Whose Account the Securities are To Be Sold	Nagendran Sukumar
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Jefferies LLC 520 Madison Avenue 4th Fl New York NY 10022	200000	1298000.00	324860000	07/10/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/02/2024	Stock Option Grant	Taysha Gene Therapies, Inc.			132063	01/02/2024	N/A
Common	01/02/2025	Stock Option Grant	Taysha Gene Therapies, Inc.			67937	01/02/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Sukumar Nagendran 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247	Common	04/10/2026	200000	831300.00

144: Remarks and Signature

Remarks	All Sales are to be made pursuant to a previously signed/adopted 10b5-1 Selling plan dated 6/11/2025 and all representations regarding material non-public information were made as of the adoption of the plan.
Date of Notice	07/10/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/11/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Sukumar Nagendran
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)